Annals of Internal MedicineThe Risk for Bleeding in Patients with Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban with Diltiazem Compared with Metoprolol

Diltiazem combined with apixaban or rivaroxaban is associated with a significantly higher serious bleeding risk versus metoprolol in atrial fibrillation patients, per a retrospective cohort study of 46,000 propensity score-matched patients published in Annals of Internal Medicine. The mechanism involves diltiazem’s potent inhibition of CYP3A4 and P-glycoprotein, key metabolic pathways for factor Xa inhibitors.

🔬 Clinical Considerations

• Bleeding risk was dose-dependent: high-dose diltiazem (>120 mg/d) produced a rate difference of 9.2 per 1,000 person-years vs 2.6 for low-dose, compared to metoprolol
• 12-month absolute risk difference of 0.48 percentage points may appear modest but compounds significantly across a large AF patient population
• Metoprolol carries no CYP3A4 interaction with factor Xa inhibitors, making it the lower-risk rate-control alternative when anticoagulation is required
• Residual confounding remains a limitation given the observational design; causal inference requires validation in prospective studies

⚡ Practice Applications

• Audit current AF patients on concurrent diltiazem and apixaban or rivaroxaban for bleeding risk
• Prioritize metoprolol over diltiazem for rate control when factor Xa inhibitors are prescribed
• Reduce diltiazem to lowest effective dose if discontinuation is not clinically feasible
• Counsel patients on bleeding warning signs when combination therapy cannot be avoided

More in Hematology